|
|
Volumn 163, Issue 12, 2006, Pages 2029-2031
|
|
The costs of drugs for schizophrenia
|
|
Author keywords
[No Author keywords available]
|
|
Indexed keywords
CLOZAPINE;
NEUROLEPTIC AGENT;
OLANZAPINE;
PERPHENAZINE;
QUETIAPINE;
RISPERIDONE;
ZIPRASIDONE;
CARDIOVASCULAR DISEASE;
CLINICAL TRIAL;
COST EFFECTIVENESS ANALYSIS;
DIABETES MELLITUS;
DISEASE COURSE;
DRUG COST;
DRUG SUBSTITUTION;
DRUG WITHDRAWAL;
EDITORIAL;
HEALTH CARE COST;
HUMAN;
METABOLIC SYNDROME X;
OUTPATIENT;
PRIORITY JOURNAL;
QUALITY ADJUSTED LIFE YEAR;
SCHIZOPHRENIA;
TARDIVE DYSKINESIA;
TREATMENT DURATION;
TREATMENT OUTCOME;
|
|
EID: 33846269663
PISSN: 0002953X
EISSN: None
Source Type: Journal
DOI: 10.1176/ajp.2006.163.12.2029 Document Type: Editorial |
|
Times cited : (17)
|
|
References (2)
|
